182 related articles for article (PubMed ID: 7558245)
1. Interferon-gamma and lipopolysaccharide reduce cAMP responses in cultured glial cells: reversal by a type IV phosphodiesterase inhibitor.
Patrizio M; Costa T; Levi G
Glia; 1995 Jun; 14(2):94-100. PubMed ID: 7558245
[TBL] [Abstract][Full Text] [Related]
2. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 Tat protein decreases cyclic AMP synthesis in rat microglia cultures.
Patrizio M; Colucci M; Levi G
J Neurochem; 2001 Apr; 77(2):399-407. PubMed ID: 11299302
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
[TBL] [Abstract][Full Text] [Related]
6. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators.
Derian CK; Santulli RJ; Rao PE; Solomon HF; Barrett JA
J Immunol; 1995 Jan; 154(1):308-17. PubMed ID: 7995950
[TBL] [Abstract][Full Text] [Related]
8. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition.
Turner CR; Esser KM; Wheeldon EB
Circ Shock; 1993 Mar; 39(3):237-45. PubMed ID: 8384094
[TBL] [Abstract][Full Text] [Related]
10. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
[TBL] [Abstract][Full Text] [Related]
11. delta-Opioid receptor activates cAMP phosphodiesterase activities in neuroblastoma x glioma NG108-15 hybrid cells.
Law PY; Loh HH
Mol Pharmacol; 1993 May; 43(5):684-93. PubMed ID: 8388986
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site.
Barnette MS; Grous M; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 Jun; 273(3):1396-402. PubMed ID: 7791113
[TBL] [Abstract][Full Text] [Related]
13. The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo.
Beshay E; Croze F; Prud'homme GJ
Clin Immunol; 2001 Feb; 98(2):272-9. PubMed ID: 11161985
[TBL] [Abstract][Full Text] [Related]
14. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
[TBL] [Abstract][Full Text] [Related]
15. In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor.
Foissier L; Lonchampt M; Cogé F; Canet E
J Pharmacol Exp Ther; 1996 Sep; 278(3):1484-90. PubMed ID: 8819536
[TBL] [Abstract][Full Text] [Related]
16. The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-alpha (TNFalpha) production in mice: effect of adrenalectomy.
Cheng JB; Watson JW; Pazoles CJ; Eskra JD; Griffiths RJ; Cohan VL; Turner CR; Showell HJ; Pettipher ER
J Pharmacol Exp Ther; 1997 Feb; 280(2):621-6. PubMed ID: 9023272
[TBL] [Abstract][Full Text] [Related]
17. Activation and induction of cyclic AMP phosphodiesterase (PDE4) in rat pulmonary microvascular endothelial cells.
Zhu B; Kelly J; Vemavarapu L; Thompson WJ; Strada SJ
Biochem Pharmacol; 2004 Aug; 68(3):479-91. PubMed ID: 15242814
[TBL] [Abstract][Full Text] [Related]
18. Cyclic nucleotide-mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity. Selective effect of cyclic AMP.
Maurice DH
Cell Biochem Biophys; 1998; 29(1-2):35-47. PubMed ID: 9631237
[TBL] [Abstract][Full Text] [Related]
19. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
[TBL] [Abstract][Full Text] [Related]
20. The role of cyclic-AMP on arginase activity by a murine macrophage cell line (RAW264.7) stimulated with lipopolysaccharide from Actinobacillus actinomycetemcomitans.
Sosroseno W; Musa M; Ravichandran M; Fikri Ibrahim M; Bird PS; Seymour GJ
Oral Microbiol Immunol; 2006 Dec; 21(6):347-52. PubMed ID: 17064391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
